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 There is still lack of consensus among different guidelines about the right timing for starting non-invasive 
mechanical ventilation (NIMV) in amyotrophic lateral sclerosis (ALS) [1-3]. The importance of 
spirometry as a reliable prognostic factor in ALS has been widely recognized; conversely, very few 
studies investigated the role of arterial blood gas analysis (ABG). Being respiratory failure the main cause 
of death in ALS, we aimed at investigating the role of ABG as proxy of Pulmonary Function Tests (PFTs)  
in a large cohort of ALS patients, identifying the best cut-off values for Forced Vital Capacity (FVC%), 
carbon dioxide (pCO2), carbonate (HCO3-) and standard base excess (SBE) to predict NIMV starting and 
survival. 
We included 488 patients with concomitant ABGs, PFTs, and ALSFRS-r score, followed in the Turin 
ALS Center, resident in Piemonte and Valle d’Aosta, diagnosed between 2000 and 2015, excluding 
patients with severe pulmonary and kidney comorbidities. Descriptive statistic of the population is shown 
in Supplementary materials. Two-hundred and seventy-four patients (56.1%) underwent NIMV. Median 
time between ABG/PFT and NIMV initiation was 5.0 months (IQR 1.0-12.0). NIMV was started at a 
median FVC% value of 57.4% (IQR 44.2-73.6). Median overall survival after NIMV initiation was 225 
days (IQR 104-491). Patients who did not undergo NIMV (N=214) were significantly older (68.6 years vs 
64.9 years, p<0.001) and had a shorter overall median survival (2.3 years, IQR 1.5-3.5 vs 2.6 years, IQR 
1.9-4.0, p=0.003). 
ABG parameters showed a significant correlation with ALSFRS-r respiratory sub-score (for pCO2 r= -
0.301; for HCO3- r= -0.290; for SBE r= -0.291; p<0.001 for all parameters) and with FVC% values (for 
pCO2 r= -0.350; for HCO3- r= -0.345; for SBE r= -0.325; p<0.001 for all parameters).  
A significant decline in FVC% was recorded when pCO2 exceeded 42 mmHg, or HCO3- exceeded 26 
mmol/L, or SBE exceeded 2 mmol/L (Table 1). Moreover, patients who had a single HCO3- increase 
(>26 mmol/L) showed reduced FVC% values; a further significant decline in FVC% was observed when 
both pCO2 and HCO3-were increased (Table 1). Therefore ABG parameters seem to predict pulmonary 
 function decline even when there is an isolated increase of HCO3- levels and also at pCO2 levels lower 
than the values commonly used to prescribe NIMV. 
ROC curves showed that the most sensitive and specific cut-offs for starting NIMV within 3 months 
were: 70% for FVC%, 42 mmHg for pCO2, 26 mmol/L for HCO3-, and 2 mmol/L for SBE (see 
Supplementary material). Interestingly, the sensitivity and specificity of ABG measures were not 
influenced by neither type of onset (bulbar/spinal) nor the presence of bulbar dysfunction at time of ABG.  
ABG/PFT values were predictive of death/tracheostomy only in patients who did not undergo NIMV. 
Risk of death/tracheostomy increased significantly by 83.0% when pCO2 reached 42 mmHg. 
Taken together, our data indicate that the use of current guidelines for NIMV initiation could lead to a 
delayed treatment of respiratory failure in ALS patients, since we found a significant increase in death 
risk already when pCO2 blood levels were above 42 mmHg and FVC values dropped below 80%. 
Moreover, the current values of pCO2 and FVC% used for NIMV indication have a reduced sensitivity 
for NIMV starting within 3 months in comparison with cut-offs of 42 mmHg for pCO2 and of 80% for 
FVC%. 
HCO3- elevation alone without significant pCO2 elevation occurred in about 25% of our patients, being a 
day-time marker of nocturnal hypoventilation (NH). NH is the first sign of respiratory failure in 
neuromuscular disorders [4] and one of the most frequent sleep disturbances in ALS, which is sometimes 
underestimated [5]. The frequency of respiratory symptoms did not differ between patients with normal 
ABG and those who showed a single HCO3- increase. Respiratory symptoms became more common only 
when both pCO2 and HCO3- increased (dyspnea  in 53.1% and orthopnea in 42.0% of cases; p<0.001 for 
both). Based on these data, NH is a frequently asymptomatic entity, associated with a high risk for 
starting NIMV at 3 months (increase of HR by 54.7% and 45.9% when HCO3- and SBE were above 26.0 
mmol/L and 2.0 mmol/L, respectively). As a compensatory mechanism, HCO3- elevation is related to a 
respiratory drive reduction with consequent worsening of hypercapnia. Current guidelines do not consider 
 blood HCO3- levels as a criterion to start ventilation [1,2,3]. According to our findings, after excluding 
any metabolic cause, we suggest that ALS patients could benefit from NIMV also in presence of an 
isolated increase of blood HCO3-/SBE levels. 
Survival analysis confirmed our data: patients with normal pCO2 and HCO3- values at ABG survived 
longer than patients with normal pCO2 and increased HCO3- (1.39 years, IQR 1.23-1.55 vs 0.87 years, 
IQR 0.73-1.02; p<0.001) and patients with increased pCO2 and HCO3- levels (0.75 years, IQR 0.60-0.90; 
p<0.001, see Supplementary material).  
The clinical-based retrospective nature of our study did not allow us to investigate other different PFTs, 
that have been proposed for respiratory function monitoring, such as maximal inspiratory/expiratory 
pressure (MIP/MEP) and/or sniff nasal inspiratory pressure (SNIP). However, their use is less considered 
than FVC/SVC in respiratory assessment and particularly in clinical trials.  
ABG, though being minimally invasive, is a sensitive, easy to perform, and inexpensive tool for 
monitoring respiratory function in ALS patients, and turned out to correlate with FVC. Unlike other 
PFTs, ABG does not require patient collaboration and is not influenced by bulbar involvement. Moreover, 
it can detect NH, a clinical condition which is frequently underestimated in patients with neuromuscular 
disorders. 
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 Table 1. Median FVC% values for different values of pCO2, HCO3- and SBE and for combined 
pCO2/HCO3- cut-offs. Comparison of FVC% values at modifying of each ABG parameter. Mann-
Whitney U test comparing each ABG parameter range to the previous one (p value < 0.05 was considered 
significant and significant values are written in bold). 
 
ABG parameter 
FVC% 
(Median value, IQR) 
p* 
pCO2   
≤39.0 mmHg 82.7 (68.5-96.4)  
39.1-42.0 mmHg 79.0 (60.7-96.3) 0.205 
42.1-45.0 mmHg 64.2 (49.6-81.3) 0.007 
>45.0 mmHg 60.1 (43.2-71.0) 0.386 
HCO3-   
≤22.0 mmol/L 85.7 (65.4-99.2)  
22.1-24.0 mmol/L 85.6 (71.8-96.4) 0.899 
24.1-26.0 mmol/L 81.7 (66.2-97.3) 0.256 
26.1-28.0 mmol/L 71.0 (57.6-87.2) <0.001 
>28.0 mmol/L 60.0 (44.4-73.2) <0.001 
SBE   
≤2.0 mmol/L 82.3 (67.4-96.7)  
2.1-3.0 mmol/L 74.1 (54.5-95.0) 0.028 
3.1-4.0 mmol/L 66.3 (60.3-81.0) 0.042 
>4.0 mmol/L 56.2 (43.7-73.5) 0.014 
Combined pCO2/HCO3- (pCO2 cut-off = 45 mmHg)   
pCO2 ≤45.0 mmHg & HCO3- ≤ 26.0 mmHg 83.4 (67.9-97.0)  
pCO2 ≤ 45.0 mmHg & HCO3- > 26.0 mmHg 70.5 (56.0-88.0) <0.001 
pCO2 >45.0 mmHg & HCO3- > 26.0 mmHg 60.0 (42.8-71.0) <0.001 
Combined pCO2/HCO3- (pCO2 cut-off = 42 mmHg)   
pCO2 ≤ 42.0 mmHg& HCO3- ≤ 26.0 mmHg 83.4 (67.9-97.9)  
pCO2 ≤ 42.0 mmHg& HCO3- > 26.0 mmHg 75.2 (61.0-92.4) 0.008 
pCO2 > 42.0 mmHg& HCO3- > 26.0 mmHg 60.9 (44.3-72.8) <0.001 
 
eTable 1. Demographic characteristics and ABGs/PFTs values. Patients who underwent NIMV vs 
patients who did not undergo NIMV. Differences of discrete and continuous variables were analyzed using 
the χ2 test and Mann-Whitney U test respectively. ΔALSFRS-R = (48- ALSFRS-R score at ABG)/disease 
duration. 
 
* Significant p values (<0.05) are written in bold 
  
 All patients NIMV No NIMV  
 Median (IQR) Median (IQR) Median (IQR) p* 
Age at onset (years) 66.3 (59.0-72.1) 64.9 (57.4-70.2) 68.6 (61.1-73.0) <0.001 
FVC (%) 75.8 (57.9-92.3) 74.6 (54.8-89.6) 79.2 (61.7-92.3) 0.009 
FEV1 (%) 77.8 (58.5-95.6) 75.9 (56.4-93.8) 81.4 (61.3-97.1) 0.051 
pH 7.43 (7.41-7.44) 7.42 (7.40-7.44) 7.43 (7.41-7.45) 0.005 
pCO2 (mmHg) 40.0 (37.0-43.0) 40.8 (38.0-44.7) 39.0 (36.2-41.5) <0.001 
pO2 (mmHg) 81.0 (73.8-87.0) 80.0 (72.6-85.7) 82.1 (76.0-87.5) 0.020 
HCO3- (mmol/l) 25.5 (23.7-27.3) 25.7 (24.0-28.0) 25.0 (23.5-26.6) <0.001 
SBE (mmol/l) 1.37 (-0.20-3.12) 1.66 (0.03-3.66) 0.85 (-0.54-2.65) 0.001 
Δ ALSFRS-R (points/month) 0.55 (0.33-1.00) 0.52 (0.31-0.92) 0.62 (0.33-1.07) 0.095 
Overall survival (years) 2.5 (1.7-3.8) 2.6 (1.9-4.0) 2.3 (1.5-3.5) 0.003 
Onset-ABG/PFT interval (years) 1.1 (0.7-1.8) 1.1 (0.7-1.8) 1.1 (0.7-1.8) 0.814 
ABG/PFT-death/tracheostomy interval (years) 1.2 (0.6-2.0) 1.4 (0.7-2.0) 0.9 (0.5-1.8) <0.001 
 n (%) n (%) n (%) p
#
 
Sex     
Male 273 (55.9%) 166 (60.6%) 107 (50.0%) 0.019 
Female 215 (44.1%) 108 (39.4%) 107 (50.0%)  
Type of onset     
Bulbar  onset 170 (34.8%) 90 (32.8%) 80 (37.4%) 0.064 
Spinal onset 318 (65.2%) 184 (67.2%) 134 (62.6%)  
Respiratory symptoms at ABG/PFT     
Dyspnea (ALSFRS-R 10 < 4) 131 (26.8%) 84 (30.7%) 47 (22.0%) 0.032 
Orthopnea (ALSFRS-R 11 < 4) 103 (21.1%) 66 (24.1%) 37 (17.3%) 0.068 
Both (ALSFRS-R 10 & 11< 4) 92 (18.9%) 61 (22.3%) 31 (14.5%) 0.029 
No symptoms 346 (70.9%) 185 (67.5%) 161 (75.2%) 0.063 
Total 488 (100%) 274 (56.1%) 214 (43.9%)  
eFigure1.  Box-plot for median value of FVC% for different ABG parameters (pCO2, HCO3-, SBE; figures 
A, B, C) and for different ABG groups (figure D). 
 
  
eFigure2. ROC curves for different cut-off values of FVC%, pCO2, HCO3- and SBE. Sensitivity and 
specificity for starting NIMV at 3 months from ABG/PFT. 
 
  
eTable2. Sensitivity and specificity for NIMV starting in 3 months. Best cut-off values for FVC%, pCO2, 
HCO3- and SBE based on Youden Index and area under the curve (AUC). Youden Index was calculated using 
Youden J statistic formula (J = sensitivity + specificity – 1 ). The best value for each parameter are written in 
bold. * p-values <0.05 was considered as significant.  
Parameter Cuts-off Sensitivity Specificity 
Youden 
Index 
AUC p* 
FVC (%) 100 96.6% 20.0% 0.166 0.583 0.021 
 90 94.1% 38.6% 0.327 0.663 <0.001 
 80 85.6% 61.4% 0.470 0.735 <0.001 
 70 70.3% 77.9% 0.482 0.741 <0.001 
 60 54.2% 86.2% 0.404 0.702 <0.001 
 50 35.6% 91.7% 0.273 0.637 <0.001 
pCO2 
(mmHg) 
40.0 68.0% 62.7% 0.307 0.654 <0.001 
 41.0 63.1% 70.6% 0.337 0.669 <0.001 
 42.0 62.3% 80.4% 0.427 0.713 <0.001 
 43.0 54.1% 86.3% 0.404 0.702 <0.001 
 44.0 45.9% 90.2% 0.361 0.680 <0.001 
 45.0 41.0% 92.2% 0.332 0.666 <0.001 
HCO3- 
(mmol/L) 
22.0 94.2% 13.0% 0.007 0.536 0.309 
 24.0 81.0% 36.3% 0.173 0.586 0.015 
 26.0 66.1% 77.4% 0.435 0.718 <0.001 
 28.0 37.2% 93.2% 0.304 0.652 <0.001 
SBE 
(mmol/L) 
1.0 78.7% 51.0% 0.297 0.648 <0.001 
 2.0 66.4% 71.9% 0.383 0.691 <0.001 
 3.0 52.5% 83.7% 0.362 0.681 <0.001 
 4.0 39.3% 92.2% 0.315 0.658 <0.001 
 
  
eTable3. Comparison of AUC values in ROC curves (diagnostic ability of discrimination for starting 
NIMV at 3 months) between patients with bulbar/spinal onset and between bulbar/no bulbar 
dysfunction at time of ABG/PFT. No significant differences were found in AUC subdividing patients by site 
of onset and by bulbar involvement at time of ABG/PFT performance.   
Parameter AUC p* 
 Bulbar onset Spinal onset  
pCO2 0.752 0.702 0.420 
HCO3- 0.761 0.716 0.466 
SBE 0.755 0.709 0.458 
FVC% 0.772 0.768 0.936 
 Bulbar dysfunction No bulbar dysfunction  
pCO2 0.691 0.770 0.180 
HCO3- 0.708 0.773 0.255 
SBE 0.703 0.758 0.355 
FVC% 0.746 0.813 0.164 
 
AUC: Area under the curve * p values was considered significant when <0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
eTable4. Hazard ratios (HR) for death/tracheostomy and NIMV starting, divided by each cut-off value 
for CO2, HCO3-, SBE blood levels and FVC% in patients who underwent and did not undergo NIMV. 
Cox proportional hazard models adjusted for sex, age at onset, site of onset (bulbar/spinal), time between onset 
and ABG/PFT, ALSFRS-r items 10 and 11. * p-values <0.05 was considered as significant and written in bold 
 NO NIMV (n=214) 
 
NIMV (n=274) 
 
Risk for 
death/tracheostomy 
 Risk for 
death/tracheostomy 
Risk for NIMV 
pCO2 cut-off HR (95% CI) p* 
 
HR (95% CI) p* HR (95% CI) p* 
40 mmHg 
1.362 
(1.007-1.842) 
0.045 
 1.058 
(0.815-1.373) 
0.674 
1.428 
(1.100-1.854) 
0.007 
41 mmHg 
1.397 
(1.009-1.935) 
0.044 
 1.017 
(0.779-1.328) 
0.901 
1.352 
(1.034-1.768) 
0.027 
42 mmHg 
2.227 
(1.525-3.254) 
< 0.001 
 1.110 
(0.841-1.465) 
0.460 
1.638 
(1.233-2.176) 
0.001 
43 mmHg 
3.501 
(2.266-5.410) 
< 0.001 
 1.170 
(0.876-1.563) 
0.288 
1.815 
(1.343-2.453) 
< 0.001 
44 mmHg 
3.716 
(2.253-6.128) 
< 0.001 
 1.026 
(0.748-1.408) 
0.872 
1.638 
(1.184-2.267) 
0.003 
45 mmHg 
4.558 
(2.586-8.035) 
< 0.001 
 1.135 
(0.819-1.573) 
0.448 
1.704 
(1.219-2.381) 
0.002 
HCO3- cut-off   
 
    
22 mmol/L 
1.471 
(0.959-2.256) 
0.077 
 0.859 
(0.555-1.328) 
0.494 
1.065 
(0.680-1.668) 
0.783 
24 mmol/L 
1.315 
(0.984-1.757) 
0.064 
 1.052 
(0.788-1.403) 
0.732 
1.006 
(0.726-1.394) 
0.970 
26 mmol/L 
1.509 
(1.077-2.114) 
0.017 
 1.123 
(0.860-1.467) 
0.395 
1.553 
(1.181-2.040) 
0.002 
28 mmol/L 
2.562 
(1.318-4.981) 
0.006 
 1.027 
(0.726-1.454) 
0.880 
1.611 
(1.124-2.309) 
0.009 
SBE cut-off   
 
    
1.0 mmol/L 
1.362 
(1.017-1.825) 
0.038 
 1.039 
(0.790-1.366) 
0.784 
1.076 
(0.797-1.452) 
0.632 
2.0 mmol/L 
1.555 
(1.149-2.106) 
0.004 
 1.071 
(0.820-1.397) 
0.616 
1.535 
(1.177-2.000) 
0.002 
3.0 mmol/L 
1.624 
(1.132-2.330) 
0.008 
 1.169 
(0.882-1.549) 
0.277 
1.328 
(1.002-1.760 
0.048 
4.0 mmol/L 
2.665 
(1.660-4.278) 
< 0.001 
 1.034 
(0.745-1.435) 
0.841 
1.476 
(1.054-2.069) 
0.024 
FVC% cut-off   
 
    
100% 
1.556 
(1.106-2.189) 
0.011 
 0.796 
(0.533-1.188) 
0.264 
1.799 
(1.223-2.648) 
0.003 
90% 
1.728 
(1.286-2.321) 
< 0.001 
 0.882 
(0.627-1.241) 
0.472 
2.189 
(1.605-2.985) 
< 0.001 
80% 
2.147 
(1.595-2.890) 
< 0.001 
 1.228 
(0.919-1.640) 
0.165 
2.611 
(1.960-3.477) 
< 0.001 
70% 
2.048 
(1.505-2.789) 
< 0.001 
 1.134 
(0.851-1.512)  
0.390 
2.920 
(2.208-3.862) 
< 0.001 
60% 
1.927 
(1.333-2.784) 
< 0.001 
 1.146 
(0.852-1.542) 
0.367 
2.296 
(1.666-3.164) 
< 0.001 
50% 
2.665 
(1.704-4.166) 
< 0.001 
 1.113 
(0.799-1.550) 
 0.526 
1.872 
(1.288-2.722) 
< 0.001 
 
  
eFigure3. Kaplan-Meier curves for median survival from time of ABG. Patients were grouped according 
to ABG values of pCO2 and HCO3- (pCO2  and HCO3- were considered increased if > 45 mmHg and >26 
mmol/L, respectively). Patients who showed normal pCO2 and HCO3- levels showed a longer survival than 
patients with a single HCO3- increase (1.39 years vs 0.87 years, log-rank test p <0.001) and those with both 
pCO2 and HCO3- increased (0.75 years, log rank test p <0.001). 
 
